First, heavy! Shanghai merger and reorganization action plan announcedHowever, it is a great pity that the China stock market has never had a history of retail investors and institutions getting rich together. Don't deal with hot money and quantification! Foreign investment in A-shares has also become stale and has become fond of speculation. There are always too many routines to create A shares, which is too tiring to play, and the experience is really bad.Among them, the biggest benefit is the biomedical industry. It is necessary to set up a M&A fund with a scale of 10 billion, which is specifically aimed at the merger and reorganization of the biomedical industry! The focus is on local enterprises in Shanghai, especially the biomedicine of listed companies in Shanghai.
First, heavy! Shanghai merger and reorganization action plan announcedNews:Easy to change the world: shareholders intend to reduce their holdings by no more than 3.05% in total;
Haineng Industry: The controlling shareholder intends to reduce the company's shares by no more than 3%;Guoxin Technology: shareholders such as the National Fund intend to reduce their holdings by no more than 3%;Contemporary Amperex Technology Co., Limited announced that the company plans to pay dividends with 15% of the net profit in the first three quarters of 2024, that is, 5.4 billion yuan as the total distribution, and distribute a cash dividend of 12.3 yuan to all shareholders for every 10 shares. In addition, Contemporary Amperex Technology Co., Limited and Stellantis plan to jointly set up a joint venture company in Spain, with each party holding 50% of the shares. The estimated total investment of the battery factory is 4.038 billion euros.
Strategy guide 12-13
Strategy guide 12-13
Strategy guide
Strategy guide 12-13
Strategy guide
12-13